FIB-4 Score Guide: MASLD Cutoffs, Age Limits & ELF 2-Step
FIB-4 = age/AST/ALT/platelet fibrosis index. Age cutoffs (35-65: 1.3/2.67; ≥65: 2.0/2.67), AASLD 2023, EASL 2024 plus ELF 2-step strategy and pitfalls.
Why FIB-4 became the universal first move
Population-scale liver fibrosis screening in the MASLD era — tens of millions of patients per year — exceeds the capacity of biopsy and imaging. FIB-4 cuts through that constraint by relying on routine blood values (AST, ALT, platelets) and age alone, allowing clinicians to triage F3-4 risk with zero incremental cost or reagent dependency.
This guide walks through the Sterling 2006 origin formula, the McPherson 2017 age-stratified cutoffs, the AASLD 2023, EASL-EASD-EASO 2024, and AGA 2026 stepwise risk-stratification pathways, the FIB-4 + ELF sequential strategy, and the typical false-positive and false-negative pitfalls — in the order of clinical decision making. Pair this with the ELF score complete guide, PRO-C3 and ECM turnover biomarkers, the comprehensive MASLD/MASH biomarker review, and the non-invasive biomarker overview.
1. The FIB-4 formula: age × AST ÷ (platelet × √ALT)
Sterling and colleagues developed FIB-4 to predict significant fibrosis in HIV/HCV coinfected patients1. It has since been validated across HCV monoinfection, MASLD/NAFLD, alcohol-related liver disease, primary biliary cholangitis, and broader chronic liver disease.
Formula
FIB-4 = (Age [years] × AST [U/L]) / (Platelet count [10⁹/L] × √ALT [U/L])
What each variable captures
| Variable | Biology | How it is obtained |
|---|---|---|
| Age | Surrogate for cumulative fibrogenesis time | History |
| AST | Hepatocyte injury and progressive fibrosis | Routine blood panel |
| ALT | Hepatocyte injury (the AST/ALT ratio also flags advanced disease) | Routine blood panel |
| Platelets | Decline reflects portal hypertension and hypersplenism | Routine blood panel |
An AST/ALT ratio >1 suggests advanced fibrosis or cirrhosis and pushes the FIB-4 score upward. Falling platelets are an early signal of portal hypertension and contribute to the cirrhosis case. For deeper context, see Compensated vs Decompensated Cirrhosis: MASH Endpoint Guide.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. Age-stratified cutoffs: the McPherson 2017 update
Standard cutoffs (35-65 years)
| FIB-4 | Interpretation | Referral decision |
|---|---|---|
| <1.3 | Low risk for F3-4 advanced fibrosis | Continue primary care follow-up |
| 1.3-2.67 | Indeterminate | Tier-2 evaluation (VCTE / ELF) |
| >2.67 | High risk for advanced fibrosis | Refer to hepatology |
Modified cutoffs for patients ≥65 years
McPherson and colleagues (Am J Gastroenterol 2017) demonstrated that the conventional 1.3 threshold drives a sharp drop in specificity (down to ~70%) in patients ≥65, producing excess specialist referrals2. The proposed age-stratified cutoffs:
| Age | Low risk | Indeterminate | High risk |
|---|---|---|---|
| 35-65 years | <1.3 | 1.3-2.67 | >2.67 |
| ≥65 years | <2.0 | 2.0-2.67 | >2.67 |
Both the AASLD 2023 Practice Guidance3 and EASL-EASD-EASO 2024 MASLD CPG4 adopt these age-stratified cutoffs as standard.
Caveats for patients <35
In patients younger than 35, the small age numerator deflates FIB-4 scores, masking advanced fibrosis (false negatives). With young-onset MASLD/MASH on the rise, individualized assessment incorporating obesity, type 2 diabetes, and family history is recommended in this age group.
3. AASLD 2023 and EASL-EASD-EASO 2024: stepwise algorithms
AASLD 2023 (Rinella ME et al., Hepatology 2023)
The AASLD 2023 Practice Guidance3 places FIB-4 as the first-line screen for MASLD (formerly NAFLD):
- Apply FIB-4 in patients with type 2 diabetes, obesity, or metabolic syndrome
- FIB-4 >1.3: proceed to VCTE (FibroScan) for second-tier liver stiffness assessment
- Refer to gastroenterology/hepatology based on VCTE thresholds (>8 kPa or >12 kPa)
PRO-C3, ELF, and other serum biomarkers are deployed to refine accuracy in the FIB-4 indeterminate range (1.3-2.67). See PRO-C3 and ECM turnover biomarkers and MASLD/MAFLD nomenclature for context.
EASL-EASD-EASO 2024 (J Hepatol 2024)
The EASL-EASD-EASO 2024 MASLD CPG4 explicitly flags FIB-4 limitations and locks in a stepwise approach:
- Step 1: apply FIB-4 in patients with type 2 diabetes, obesity, metabolic risk factors, abnormal liver enzymes, or imaging-detected steatosis
- Step 2: rule in/out F≥2 with VCTE or other elastography
- Limitations: indeterminate range (1.3-2.67), elderly patients, and specific comorbidities reduce accuracy
- Treatment linkage: where locally approved, resmetirom may be considered in non-cirrhotic MASH with F≥2 meeting label criteria; FIB-4 alone does not determine eligibility
Resmetirom labeling, eligibility logic, and the trial-design implications are detailed in Resmetirom Post-Approval MASH Strategy, MASH Drug Landscape 2025, Liver Antifibrotic Drug Landscape 2026, MASH Combination Therapy Pipeline 2026, Efruxifermin (HARMONY/SYMMETRY), and Fibrosis Market Size 2026.
AGA 2026 clinical care pathway
The AGA 2026 clinical care pathway (Gastroenterology 2026) likewise places FIB-4 as step 1 and VCTE/FibroScan or ELF as step 2, managing FIB-4 <1.3 (<2.0 for ≥65) as low risk in primary care and escalating elevated FIB-4 to VCTE or ELF. For ELF, <9.2 indicates low risk while ≥9.8 suggests clinically significant fibrosis — so the ELF ≥9.8 used here corresponds to the higher-risk threshold.
4. The FIB-4 + ELF two-step algorithm: complementary sensitivity and specificity
Why two tiers
At low cutoffs, FIB-4 has high NPV and is useful for rule-out; at high cutoffs it helps rule in higher-risk patients, though its sensitivity is lower than ELF. ELF has the complementary profile — high sensitivity for advanced fibrosis but constrained by cost and the requirement for a Siemens ADVIA Centaur analyzer. Sequential use leverages low-cost FIB-4 as the primary filter and high-sensitivity ELF as the second-line refinement5.
Algorithm in practice
Step 1: FIB-4 ≥1.3 → proceed to Step 2
Step 2: ELF ≥9.8 → refer for VCTE / MRE / biopsy
ELF <9.8 → continue surveillance (annual reassessment)
Performance data (Kang et al., Diagnostics 2024)
For detecting F3-4 advanced fibrosis in MASLD8:
| Metric | FIB-4 alone | FIB-4 + ELF (sequential) |
|---|---|---|
| Sensitivity | Moderate | 67.86-85% |
| Specificity | Moderate | 90.40% |
| PPV | Low-Moderate | 75-81% |
| NPV | High | 79-87% |
| AUROC | 0.65-0.75 | 0.791 |
Operational implications:
- Roughly 88% reduction in unnecessary specialist referrals
- More than 50% reduction in direct specialist-pathway costs
- 4× improvement in advanced-fibrosis detection sensitivity vs FIB-4 alone
How this maps to large MASH trials
FIB-4 is often used in pre-screening or exploratory NIT analyses in trials such as ESSENCE Phase 3 (semaglutide MASH F2/F3, NEJM 2025, PMID 40305708)6 and MAESTRO-NASH (resmetirom F1B-F3, NEJM 2024, PMID 38324483)7; however, these pivotal MASH trials still rely on histologic confirmation for enrollment and endpoints.
5. Typical false-positive and false-negative pitfalls
False-positive scenarios
- Patient ≥65 years with cutoff 1.3 misapplied: switch to McPherson cutoff 2.0
- Drug-induced thrombocytopenia (post-chemotherapy, heparin-induced): low platelets inflate the score
- Thalassemia and inherited platelet disorders: structurally low platelets inflate the score
False-negative scenarios
- MASLD in patients <35: small age numerator deflates the score
- Chronic inflammation (RA, SLE) elevating platelets: because platelets are the denominator, the score is deflated and advanced fibrosis is underestimated
- Compensated cirrhosis with preserved platelet count: early cirrhosis evades detection
- MASH without AST/ALT ratio reversal: rises slowly even as fibrosis advances
Mitigation
- Always escalate the indeterminate range (1.3-2.67) to VCTE / ELF / MRE
- Apply the McPherson cutoff 2.0 strictly in patients ≥65
- Do not interpret FIB-4 during acute hepatitis, acute illness, or sharp AST/ALT spikes — reassess once stable
- Track longitudinal trajectory (6-12 month serial FIB-4) rather than single-time-point values
- Integrate clinical context — portal hypertension stigmata, full biochemistry, imaging — rather than reading FIB-4 in isolation
References
1. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-1325. PubMed
2. McPherson S, Hardy T, Dufour JF, et al. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. Am J Gastroenterol. 2017;112(5):740-751. PubMed
3. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. PubMed
4. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. PubMed
5. Kjaergaard M, Lindvig KP, Thorhauge KH, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 2023;79(2):277-286. PubMed
6. Sanyal AJ, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE Part 1). N Engl J Med. 2025;392(21):2089-2099. PubMed / NCT04822181
7. Harrison SA, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH). N Engl J Med. 2024;390(6):497-509. PubMed / NCT03900429
8. Kang YW, Baek YH, Moon SY. Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. Diagnostics (Basel). 2024;14(22):2517. PubMed
Related articles
- ELF Score Complete Guide
- PRO-C3 Clinical Use: MASH PD Marker, ADAPT, 15.6 ng/mL Cutoff
- PRO-C3 and ECM Turnover Biomarkers
- Comprehensive MASLD/MASH Biomarker Review
- Non-Invasive Fibrosis Biomarker Overview
- MASLD/MAFLD Nomenclature & Classification
- Compensated vs Decompensated Cirrhosis: MASH Endpoint Guide
- Resmetirom Post-Approval MASH Strategy
- Efruxifermin (EFX): HARMONY/SYMMETRY and the Novo Acquisition
- MASH Drug Landscape 2025
- Liver Antifibrotic Drug Landscape 2026
- MASH Combination Therapy Pipeline 2026
- Fibrosis Market Size 2026